Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Jill Corre, Valérie Lauwers‐Cancès et al.|Journal of Clinical Oncology|2019Cited by 179
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periodsJill Corre, Aurore Perrot, Cyrille Hulin et al.|Leukemia|2021Cited by 41
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25
Response to pneumococcal vaccination in multiple myelomaLoïc Renaud, Xavier Leleu, Susanna Schraen et al.|Cancer Medicine|2019Cited by 24